Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC
Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.
Novel Treatments May Have the Potential to Impact GI Cancer Care
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer
Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.
Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
The staged approach to colectomy offers survival benefits, and it may help avoid unnecessary procedures that only require appendectomy.
Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
CRC Yields Most Prevalent Data at Recent GI Meeting
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
“We did not find any benefit for any of the subgroups in our paper and our study,” Muhammad Talha Waheed, MD, stated.
EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast Cancer
Results from the phase 3 DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) monotherapy improved progression-free survival over chemotherapy in patients with breast cancer.
Tovecimig Yields Significant Responses in Advanced Biliary Tract Cancer
The prespecified number of events required to undergo analyses of the secondary end points, including PFS, OS, and DOR, have not been met.
DecisionDx-Melanoma Test Accurately Identifies Low-Risk SLN Positivity
All patients identified as low risk for sentinel lymph node positivity with the DecisionDx-Melanoma test had recurrence-free status after 3 years.
Outlining Risk Factor Identification and Mitigation in Bladder Cancer
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
Adding HIPEC to CRS did not show any added benefit but has shown increased toxicities in patients with colorectal peritoneal metastasis.
The Importance of Multidisciplinary Care in Bone Marrow Transplantation
Multidisciplinary care is important for all cancer care, specifically bone marrow transplant, stated Nina Wagner-Johnston, MD.
Telehealth Groups May Improve the Social Lives of Young Cancer Populations
Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.
Developers Terminate Clinical Program for Ociperlimab in Lung Cancer
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.
Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Metastases
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC
Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.
Immunotherapy Plus Transplantation Improves Outcomes in Relapsed Lymphoma
“Recognizing that we could follow immunotherapy with a bone marrow transplant safely was quite important,” Nina Wagner-Johnston, MD, stated.
Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Guideline Update Supports Laser Therapy for Brain Tumors After SRS
The REMASTer trial found that laser interstitial thermal therapy was equivalent to open craniotomy regarding OS and PFS data in progressive metastatic brain tumors.
A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers
Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.
Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors
Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
CHMP Grants Positive Opinion to Tislelizumab/Chemotherapy in Frontline ES-SCLC
Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma
Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.
